Filing Overview
Registrant: 8i Acquisition 2 Corp., a British Virgin Islands special purpose acquisition company (SPAC), not EUDA Health Holdings Ltd. The filing is a Form 8-K dated August 30, 2022, with a signature date of October 6, 2022.
The filing reports a Regulation FD disclosure and identifies EUDA Health Limited as a company discussed in an attached research report.
Business Context and Reporting Period
The Company retained and compensated Fundamental Research Corp. to prepare a research report concerning 8i Acquisition 2 Corp. and EUDA Health Limited. The report is dated August 30, 2022 and was furnished as Exhibit 99.1.
The provided filing text does not include the research report itself or operating and financial results for EUDA Health.
Financial Metrics and Liquidity
- Revenue, profit, cash flow, margins, debt, liquidity, and other financial metrics are not provided in the filing text.
- No balance sheet, income statement, cash flow statement, or comparable-period financial data is included.
- No guidance or quantified forecasts are provided in the filing text.
Material Changes and Other Disclosures
- The material event is the furnishing of a third-party research report prepared by Fundamental Research Corp.
- The Company states that the report was furnished pursuant to Item 7.01 and is not deemed filed for purposes of Section 18 of the Exchange Act.
- The filing identifies the Company’s Nasdaq-listed units, ordinary shares, redeemable warrants, and rights under the symbols LAXXU, LAX, LAXXW, and LAXXR, respectively.
- The filing does not describe a completed transaction, changes in ownership, financial performance, or changes versus a prior comparable period.
Outlook, Risks, and Unusual Items
The filing provides no management guidance, formal outlook, material contingencies, or detailed risk discussion. Investors should note that the research report was commissioned and compensated by the Company, which may present potential conflicts or affect the report’s objectivity.
Key Facts to Verify
- Obtain and review Exhibit 99.1 for the research report’s financial data, valuation assumptions, forecasts, and risk factors.
- Verify the corporate relationship and transaction status between 8i Acquisition 2 Corp. and EUDA Health Limited.
- Confirm whether subsequent filings provide audited financial statements or transaction-related disclosures for EUDA Health.
- Evaluate the research report’s compensation arrangement and methodology before relying on its conclusions.